NCT06315387View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetics of 4-MUST, Tablets, 128 mg (Valenta Pharm JSC) During Single and Multiple Oral Administration in Healthy Volunteers

PHASE1RecruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

December 4, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Cholecystitis
Interventions
DRUG

4-MUST, 1 tablet

4-methylumbelliferyl trimebutine sulfate, 128 mg

DRUG

4-MUST, 2 tablets

4-methylumbelliferyl trimebutine sulfate, 256 mg

DRUG

4-MUST, 3 tablets

4-methylumbelliferyl trimebutine sulfate, 384 mg

Trial Locations (1)

19119

RECRUITING

"Limited Liability Company Medical Center Eco-Safety", Saint Petersburg

All Listed Sponsors
lead

Valenta Pharm JSC

INDUSTRY